全文获取类型
收费全文 | 174271篇 |
免费 | 902篇 |
专业分类
耳鼻咽喉 | 1121篇 |
儿科学 | 6607篇 |
妇产科学 | 2989篇 |
基础医学 | 16352篇 |
口腔科学 | 1528篇 |
临床医学 | 12246篇 |
内科学 | 30493篇 |
皮肤病学 | 651篇 |
神经病学 | 16337篇 |
特种医学 | 8878篇 |
外科学 | 28658篇 |
综合类 | 2305篇 |
预防医学 | 18011篇 |
眼科学 | 2719篇 |
药学 | 9385篇 |
中国医学 | 623篇 |
肿瘤学 | 16270篇 |
出版年
2018年 | 21916篇 |
2017年 | 17359篇 |
2016年 | 19503篇 |
2015年 | 876篇 |
2014年 | 762篇 |
2013年 | 718篇 |
2012年 | 6875篇 |
2011年 | 20922篇 |
2010年 | 18759篇 |
2009年 | 11464篇 |
2008年 | 19409篇 |
2007年 | 21612篇 |
2006年 | 449篇 |
2005年 | 2075篇 |
2004年 | 3287篇 |
2003年 | 4261篇 |
2002年 | 2413篇 |
2001年 | 253篇 |
2000年 | 394篇 |
1999年 | 149篇 |
1998年 | 191篇 |
1997年 | 197篇 |
1996年 | 84篇 |
1995年 | 96篇 |
1994年 | 94篇 |
1993年 | 55篇 |
1992年 | 34篇 |
1991年 | 81篇 |
1990年 | 120篇 |
1989年 | 73篇 |
1988年 | 50篇 |
1987年 | 37篇 |
1986年 | 21篇 |
1985年 | 28篇 |
1984年 | 18篇 |
1983年 | 20篇 |
1982年 | 25篇 |
1980年 | 41篇 |
1974年 | 19篇 |
1970年 | 19篇 |
1969年 | 20篇 |
1968年 | 17篇 |
1939年 | 20篇 |
1938年 | 60篇 |
1937年 | 25篇 |
1935年 | 22篇 |
1934年 | 30篇 |
1933年 | 14篇 |
1932年 | 56篇 |
1930年 | 46篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
991.
Christian J. Hendriksz Kenneth I. Berger Rossella Parini Moeenaldeen D. AlSayed Julian Raiman Roberto Giugliani John J. Mitchell Barbara K. Burton Norberto Guelbert Fiona Stewart Derralynn A. Hughes Robert Matousek Elaina Jurecki Celeste Decker Paul R. Harmatz 《Journal of inherited metabolic disease》2016,39(6):839-847
Objective
To present long-term respiratory function outcomes from an open-label, multi-center, phase 3 extension study (MOR-005) of elosulfase alfa enzyme replacement therapy (ERT) in patients with Morquio A syndrome.Methods
In part 1 of MOR-005, patients initially randomized to ERT in the 24-week pivotal study (MOR-004) remained on their regimen (2.0 mg/kg/week or every other week); placebo patients were re-randomized to one of the two regimens. During part 2, all patients received elosulfase alfa 2.0 mg/kg/week. Respiratory function was one of the efficacy endpoints evaluated in MOR-005. Change from MOR-004 baseline to 120 weeks of treatment for the combined population was determined and compared with results from untreated patients from a Morquio A natural history study (MorCAP).Results
Maximum voluntary ventilation (MVV) improved up to week 72 and then stabilized; forced vital capacity (FVC) and forced expiratory volume in 1 s (FEV1) increased continuously over 120 weeks. Mean increases in the modified per-protocol population was 9.2 % for FVC, 8.8 % for FEV1, and 6.1 % for MVV after 120 weeks. All patients ≤14 years showed respiratory improvements, presumably in part related to growth; however, these were greater in treated patients. For those >14 years, treated patients showed improvements, while deterioration occurred in untreated. Altogether, the improvements were significantly greater (P?<?0.05) in treated patients.Conclusions
Long-term ERT is associated with sustained improvements in respiratory function in Morquio A. In younger patients (≤14 years), some improvement may be ascribed to growth. In older patients, other mechanisms, e.g., decreased glycosaminoglycan storage, are likely involved.992.
Zervos M Mandell LA Vrooman PS Andrews CP McIvor A Abdulla RH de Caprariis PJ Knirsch CA Amsden GW Niederman MS Lode H 《Treatments in respiratory medicine》2004,3(5):329-336
Objective: To compare the efficacy and tolerability of ceftriaxone plus azithromycin with those of levofloxacin in the treatment of hospitalized patients with moderate to severe community-acquired pneumonia (CAP). Design: Randomized, open-label multicenter trial with 1 : 1 treatment allocation in an inpatient setting. Patients: 212 male or female inpatients with a clinical diagnosis of CAP were included in the study. In each treatment group >50% of patients had a pneumonia severity index of IV or V. Interventions: Open-label treatment with either intravenous (IV) ceftriaxone 1g and IV azithromycin 500mg daily or IV levofloxacin 500mg daily. Patients who improved clinically were switched to oral follow-on therapy with either azithromycin 500 mg/day or levofloxacin 500 mg/day. At the clinician’s discretion, oral cefuroxime axetil was added to the treatment regimen of patients who received oral azithromycin if a macrolide resistant pneumococcal isolate was documented. Results: Overall, both study treatments were well tolerated. Favorable clinical outcomes in clinically evaluable patients were demonstrated in 91.5% of patients treated with ceftriaxone plus azithromycin and 89.3% (95% CI ?7.1%, 11.4%) of patients treated with levofloxacin at the end of therapy visit and in 89.2% and 85.1% (95% CI ?6.7%, 14.8%) patients, respectively, at the end of study visit. Bacteriological eradication rates for both treatments were equivalent with the exception of Streptococcus pneumoniae; 44% of isolates were eradicated with levofloxacin compared with 100% of isolates with ceftriaxone plus azithromycin. Conclusions: As acknowledged by international CAP treatment guidelines, the combination of a third-generation cephalosporin and a macrolide is at least as efficacious as monotherapy with a fluoroquinolone with enhanced anti-pneumococcal activity, for hospitalized patients with moderate to severe CAP. Combined medication with a macrolide and third-generation cephalosporin may be preferred over fluoroquinolones as first-line therapy of hospitalized patients with CAP to minimize the development of multiresistant nosocomial Gram-negative bacilli. 相似文献
993.
Hyperprolactinemia is commonly found in both female and male patients with abnormal sexual and/or reproductive function or with galactorrhea. If serum prolactin levels are above 200 microg/L, a prolactin-secreting pituitary adenoma (prolactinoma) is the underlying cause, but if levels are lower, differential diagnoses include the intake of various drugs, compression of the pituitary stalk by other pathology, hypothyroidism, renal failure, cirrhosis, chest wall lesions, or idiopathic hyperprolactinemia. When a pituitary tumor is present, patients often have pressure symptoms in addition to endocrine dysfunction, such as headaches, visual field defects, or cranial nerve deficits. The large majority of patients with prolactinomas, both micro- and macroprolactinomas, can be successfully treated with dopaminergic drugs as first-line treatment, with normalization of prolactin secretion and gonadal function, and with significant tumor shrinkage in a high percentage of cases. Surgical resection of the prolactinoma is the option for patients who may refuse or do not respond to long-term pharmacological therapy. Radiotherapy and/or estrogens are also reasonable choices if surgery fails. In patients with asymptomatic microprolactinoma no treatment needs to be given and a regular follow-up with serial prolactin measurements and pituitary imaging should be organized. Currently, the most commonly used dopamine agonists are bromocriptine, pergolide, quinagolide and cabergoline. When comparing the plasma half-life, efficacy and tolerability of these drugs, cabergoline seems to have the most favorable profile, followed by quinagolide. Ifprolactin levels are well controlled with dopamine agonist therapy, gradual tapering of the dose to the lowest effective amount is recommended, and in a number of cases medication can be stopped after several years. Evidence to date suggests that cabergoline and quinagolide appear to have a good safety profile for women who wish to conceive, but hard evidence proving that dopamine agonists do not provoke congenital malformations when taken during early pregnancy is currently only available for bromocriptine. Once pregnant, dopamine agonist therapy should be immediately stopped, unless growth of a macroprolactinoma is likely or pressure symptoms occur. At our institution patients with symptomatic prolactinomas, both micro- and macroadenomas, are treated with cabergoline as the first-line aproach. In the small group of patients who do not respond to this treatment, or who refuse long-term therapy, surgery is offered. Radiotherapy is given if both pharmacologic therapy and surgery fail. 相似文献
994.
Kato S Nakayama K Minoura T Konno M Tajiri H Matsuhisa T Iinuma K;Japanese pediatric Helicobacter study group 《Journal of gastroenterology》2004,39(11):1045-1050
Background As noninvasive tests for Helicobacter pylori infection, the 13C-urea breath test (UBT) and stool antigen test have been widely used. In children, however, there are few studies reporting which test shows superior performance. The purpose of this study was to compare the 13C-UBT and stool antigen test for their accuracy in diagnosing H. pylori infection in children.Methods A total of 123 Japanese children, ages 2 to 17 years (mean, 12 years) who underwent gastric biopsies for H. pylori infection were studied. The diagnoses included gastritis (n = 55), gastric ulcer (n = 5), duodenal ulcer (n = 20), iron-deficiency anemia (n = 7), and other conditions (n = 36). The cutoff value of the 13C-UBT was defined to be 3.5. The stool antigen test was performed using the HpSA enzyme-linked immunosorbent assay (ELISA) (Premier Platinum HpSA). In 16 patients who received eradication therapy, the 13C-UBT and HpSA were repeated 2 months after treatment.Results Based on biopsy tests, 60 children were infected with H. pylori and 63 children were not. For the 13C-UBT, the sensitivity, specificity, and accuracy were 95.0% (95% confidence interval [CI], 86.1%–99.0%), 98.4% (95% CI, 91.5%–100%), and 96.4% (95% CI, 93.6%–99.9%), respectively. For the HpSA, the sensitivity, specificity, and accuracy were 98.3% (95% CI, 90.8%–100%), 98.4% (95% CI, 91.2%–100%), and 98.3% (95% CI, 96.0%–100%), respectively. There were no significant differences between the performance of these two tests. In the assessment of H. pylori eradication, the results of 13C-UBT and HpSA agreed with those of biopsy tests.Conclusions The 13C-UBT and the HpSA are equally accurate for the diagnosis of active H. pylori infection in Japanese children.Kazuie Iinuma, for the Japanese Pediatric Helicobacter study Group 相似文献
995.
996.
Opinion statement The prevalence of congestive heart failure is progressively increasing and despite recent advances in therapeutics, there
is a continuing need for novel effective therapies. New, investigational treatment strategies include inotropic drugs, neurohormonal
antagonists, anticytokine and anti-inflammatory strategies, hormonal therapies, and nutritional supplements. Current positive
inotropes (eg, dobutamine and phosphodiesterase inhibitors) provide symptomatic relief, but newer agents may have a better
adverse effect profile. Angiotensin-converting enzyme (ACE) inhibitors should remain first-line treatment with angiotensin
receptor blockers used in ACE inhibitor-intolerant patients. Many new neurohormonal antagonists have recently been investigated
and eplerenone has demonstrated clinical benefit. New hormonal, anticytokine, and anti-inflammatory therapies have shown benefit
in small trials, but results in larger trials have been disappointing. Other approaches are currently being tested in large
trials that will clarify their role. Nutritional supplements need to be tested in a large prospective trial before they can
be recommended. 相似文献
997.
Koutroubakis IE Petinaki E Dimoulios P Vardas E Roussomoustakaki M Maniatis AN Kouroumalis EA 《International journal of colorectal disease》2003,18(3):254-259
BACKGROUND AND AIMS: Initiation of a fibrotic process has been suggested as part of the intestinal response to chronic inflammation in inflammatory bowel disease. YKL-40 has been proposed as a new serum marker of fibrosis. We studied compared the serum levels of YKL-40 in patients with ulcerative colitis or Crohn's disease with inflammatory and healthy controls. PATIENTS AND METHODS: YKL-40 serum levels were measured in 179 patients with inflammatory bowel disease (94 ulcerative colitis, 85 Crohn's disease), in 23 with intestinal inflammation of other causes, and 70 matched healthy controls using a commercially available enzyme-linked immunosorbent assay. YKL-40 levels were assessed in terms of disease activity, type and localization. RESULTS: Mean serum YKL-40 levels were 102.6+/-82.7 ng/ml in ulcerative colitis patients and 112.2+/-83.7 ng/ml in Crohn's disease patients, significantly higher than in healthy controls (64.1+/-21.4 ng/ml) but not significantly different from inflammatory controls (77.8+/-23.1 ng/ml). Disease activity and C-reactive protein levels were significantly correlated with YKL-40 levels in both ulcerative colitis and Crohn's disease. Crohn's disease patients with ileum localization had significantly higher YKL-40 levels than those with ileocolonic or colonic disease. Patients with stenotic disease had mean YKL-40 levels not significantly different than those with nonstenotic disease. CONCLUSION: Serum levels of YKL-40 are increased in patients with inflammatory bowel disease, and this is associated with the inflammatory process rather than with the degree of fibrosis. 相似文献
998.
Miller DD 《Current cardiology reports》2004,6(1):41-52
More than a decade of dramatic changes in US and global health care has affected the practice of and payment for nuclear cardiology
services. The clear diagnostic and prognostic power of nuclear cardiology procedures to detect coronary artery disease and
predict patient outcomes has resulted in the rapid growth of these procedures in clinical practice. This has focused the attention
of public and private payers on the high use of medical resources required to carry out nuclear cardiology testing. Two recent,
major multicenter trials, one in the United States and another in Europe, have demonstrated the cost effectiveness of stress
myocardial perfusion imaging strategies compared with coronary angiography in patients with known or suspected coronary artery
disease, across the spectrum of pretest risks and both sexes. These studies, and more extensive data from more than 10 years
of decision analysis, have reinforced the value of nuclear cardiology in modern cardiovascular health care. Future challenges
will include assurance of provider and laboratory quality in the burgeoning outpatient imaging centers across the country,
and wider acceptance by payers and expert panels of the evidence supporting the cost effectiveness of nuclear cardiology in
most clinical settings. 相似文献
999.
Familial Mediterranean fever (FMF) is an autosomal-recessive disease. It is characterized by recurring fever, abdominal pain, and serositis. The Mediterranean fever (MEFV) gene is localized on 16p13.3 and more than 35 mutations have been described to date. There are some differences in the gene mutations of FMF in the various ethnic groups. The aim of this study is to determine the frequency of the mutations which has been reported comparatively rare, to define the most effective mutation set, and to select the most suitable DNA analysis system for Turkish FMF patients. Mutations in 330 Turkish FMF patients with typical phenotypes from various regions of Turkey were evaluated for the research purposes. These patients were analyzed for six MEFV gene mutations by the NanoChip® Molecular Genetics Workstation. The most frequent mutation was M694V, identified in 50.00% of the alleles examined; M680I followed with 14.10% and V726A—9.70%. Consequently, we determined that R761H (n?=?23; 3.48%) was the most frequent rare mutations in Turkish FMF patients. Frequency of the rare mutations were R761H (3.48%), E148Q (1.36%), and M694I (1.21%). All of these mutations were in the compound heterozygote state. Our study showed that R761H mutations were higher than it has been reported in literature until now and were mainly associated with M694V. We suggest that mutation R761H should be included in the mutation scanning analysis researches or considered if the patient has M694V/? mutation especially in Turkish FMF patients. Larger serial studies need to be done to investigate the rate and coexistence of these mutations. 相似文献
1000.